New Dimensions in Pavement Markings Successfully Acquired by Strategic Buyer
What the Options Market Tells Us About Viking Therapeutics
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Stifel Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $95
Stifel analyst Annabel Samimy maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $95.According to TipRanks data, the analyst has a success rate of 45.2%
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Viking Therapeutics(VKTX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 53.4% and a total average return of 24.3%
Truist Financial Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
BTIG analyst Justin Zelin maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $125.According to TipRanks data, the analyst has a success rate of 40.2% and a
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Morgan Stanley analyst Michael Ulz maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $105.According to TipRanks data, the analyst has a success rate of 41.0
Morgan Stanley Reiterates Overweight on Viking Therapeutics, Maintains $105 Price Target
Buy Rating Affirmed for Viking Therapeutics as VK2735 Shows Promising Weight Loss and Safety Profile
viking therapeutics (VKTX.US) rose over 11% on Wednesday! Received a 'shareholding' rating from Morgan Stanley.
Morgan Stanley gives Viking Therapeutics a "shareholding" rating with a target price of $80 and includes the stock on its watchlist.
Why Viking Therapeutics Stock Rocked the Market Today
Why Analysts Predict a November Surge for Viking Therapeutics Stock
JPMorgan Initiates Coverage on GLP-1 Entrant Viking Therapeutics
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan